Process Development - Bioprocess: Market Size & Forecast 2026

We estimate the global bioprocess process development market at approximately USD 32.1 billion in 2025 (base year), expanding at a 9.2 percent CAGR through 2032 under our central case. The category encompasses upstream and downstream process development, analytical and formulation development, and cell-line and strain engineering services performed under contract or sponsor-retained for monoclonal antibodies, vaccines, cell and gene therapies, recombinant proteins, and biosimilars. Process-development activity is structurally tighter than commercial biomanufacturing: lead times for typical mAb process-development and scale-up programmes run 12 to 24 months, and qualification of an alternative upstream platform - especially perfusion or continuous - takes 6 to 18 months once a lead is nominated. The current demand-supply balance is moderately tight for sponsor-retained internal programmes

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.